<DOC>
	<DOCNO>NCT00669110</DOCNO>
	<brief_summary>The primary purpose study evaluate long-term safety tolerability Desvenlafaxine Succinate Sustained-Release ( DVS SR ) child adolescent outpatient major depressive disorder . A secondary aim evaluate efficacy DVS SR treatment child adolescent outpatient major depressive disorder exploratory manner .</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets ( DVS SR ) In The Treatment Of Child Adolescent Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Outpatients complete 8weeks treatment precede study , 3151A62000 , , opinion investigator , would benefit longterm treatment . Study participant surgically sterile postmenopausal must agree commit use reliable method birth control duration study 15 day last dose test article . Sexually active study participant must agree commit use condom addition contraceptive method . Clinically important abnormality baseline physical examination clinically significant abnormality electrocardiogram ( ECG ) , laboratory test result , vital sign record final study day ( day 56 visit ) precede study 3151A62000 . Unresolved clinically significant adverse event serious adverse event precede study 3151A62000 . Poor compliance precede study 3151A62000 , assess investigator medical monitor . Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>